A Randomized Phase 2 Study of SCH 727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2014
At a glance
- Drugs Dinaciclib (Primary) ; Alemtuzumab; Alemtuzumab; Bortezomib
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Merck & Co; Schering-Plough
- 09 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual patient number (8) added as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual end date (December 2010) added as reported by ClinicalTrials.gov.